Arcturus Therapeutics Holdings Inc. Sees Stake Reduction Amid Market Fluctuations

Arcturus Therapeutics Holdings Inc., a health care sector company based in San Diego, United States, has experienced a notable reduction in stake by Sumitomo Mitsui Trust Group, Inc. as of May 1, 2025. The company, which operates as a holding company through its subsidiaries, focuses on RNA therapeutics aimed at treating various diseases. It serves patients exclusively within the United States and maintains an online presence through its website, www.arcturusrx.com . Arcturus Therapeutics is listed on the Nasdaq.

Over the past year, the company’s stock has seen significant fluctuations. It reached a 52-week high of $45 USD on June 4, 2024, but subsequently fell to a 52-week low of $8.04 USD on April 6, 2025. As of May 7, 2025, the stock price closed at $11.38 USD. The company’s market capitalization stands at approximately $339 million USD.

The financial metrics reveal a complex market valuation for Arcturus Therapeutics. The price-to-earnings ratio is currently at -4.28, while the price-to-book ratio is 1.4. These figures suggest a challenging financial landscape, reflecting the broader volatility in the company’s stock performance.

The recent stake reduction by Sumitomo Mitsui Trust Group, Inc. adds another layer to the company’s ongoing financial narrative. As Arcturus Therapeutics continues to navigate the dynamic health care sector, stakeholders and investors will be closely monitoring its strategic moves and market performance.